Perrigo CO PLC 8-K filings

Perrigo Company plc announced its second quarter 2026 financial results, reporting a decrease in net sales and adjusted diluted EPS, while reaffirming its full-year outlook.

Perrigo Company plc amends prior 8-K filing to detail the employment agreement for Albert Manzone as Interim President and Chief Executive Officer, including salary, bonus, and equity grants.

Perrigo Company plc has reinstated its Executive Committee Severance Policy, offering enhanced benefits to executive officers during a leadership transition period.

Perrigo Company plc announced the appointment of Salman Amin and Omer Gajial as independent directors to its Board, effective June 30, 2026, expanding the board to ten members.

Perrigo Company plc announced the immediate resignation of its President and CEO, Patrick Lockwood-Taylor, due to personal conduct inconsistent with the company's code of conduct, appointing Albert A. Manzone as interim CEO.

Perrigo Company plc announced first quarter 2026 financial results, showing progress on its ThreeS plan despite category headwinds, and reaffirmed its full-year guidance.

Perrigo Company plc's 2026 Annual General Meeting saw shareholders approve the new 2026 Long-Term Incentive Plan, re-elect directors, and ratify auditor appointment.

Perrigo has finalized the sale of its Dermacosmetics business to Karo Healthcare for up to 332.6 million euros to streamline its portfolio and reduce debt.

Perrigo Company plc has transitioned to a product-category-based reporting structure to better align financial disclosures with its strategic priorities.

Perrigo Company plc has amended and restated its credit agreement, extending its $1.0 billion revolving credit facility to March 2031 and prepaying Term A Loans.

Perrigo announced its fourth quarter and fiscal year 2025 financial results, reporting a significant goodwill impairment while outlining strategic shifts and a new operational enhancement program.

Perrigo reports a 4.1% net sales decline in Q3 2025, initiates a strategic review of its infant formula business, and updates its full-year outlook due to soft market consumption.

Perrigo Company plc reported mixed second-quarter 2025 results, reaffirming its full-year adjusted EPS target despite net sales trending towards the lower end of guidance due to challenging market conditions and slower infant formula recovery.

Perrigo Company plc has signed an agreement to sell its Dermacosmetics branded business, including key brands ACO and Biodermal, to Kairos Bidco AB, an investment vehicle managed by KKR, for up to €327 million, advancing its strategic portfolio streamlining.

Perrigo Company plc announced a strategic organizational update, including key leadership changes and the optimization of its global Category-Led, Market Activation Growth Model, with no impact on its 2025 adjusted EPS guidance.

Perrigo Company plc has announced the retirement of its Executive Vice President of Global Operations and Supply Chain, Ronald Janish, and the appointment of industry veteran Matt Winterman as his successor, effective June 23, 2025.

Perrigo's Q1 2025 results show strong adjusted EPS growth and margin expansion, fueled by the recovery of the infant formula business, while the company widens its net sales target ranges for 2025 due to macroeconomic uncertainty.

Perrigo Company plc held its Annual General Meeting on May 1, 2025, where shareholders elected directors and approved several key proposals.

Perrigo's Q4 results show a slight net sales decline but adjusted EPS growth, while fiscal year results reflect a decrease in net sales offset by adjusted operating income growth driven by 'Project Energize'.

Perrigo Company plc has extended CEO Patrick Lockwood-Taylor's tenure, effective February 26, 2025, through an amended and restated employment agreement.

Katherine Doyle, an independent director of Perrigo Company plc, will retire from the Board at the 2025 annual general meeting.

Perrigo Company plc announces the appointment of Jonas Samuelson to its Board of Directors, effective January 15, 2025.

Perrigo has reached a settlement with its D&O insurers, securing $98 million to resolve securities litigation related to events from 2015-2017.

Perrigo's third quarter 2024 results show significant operating income growth and margin expansion, fueled by the recovery of its infant formula business and strategic initiatives.

Perrigo's third quarter results show significant operating income growth and margin expansion, driven by the infant formula business recovery and cost-saving initiatives, despite a slight decrease in net sales.

Perrigo Finance Unlimited Company successfully closed a $1.076 billion senior notes offering to refinance existing debt and for general corporate purposes.

Perrigo has voluntarily recalled 16,500 cans of store brand infant formula due to elevated levels of Vitamin D, affecting products sold at H-E-B and CVS.

Perrigo's second quarter results show a decline in net sales, primarily due to infant formula issues and lower seasonal demand, but the company maintains its full-year adjusted EPS outlook.

Todd Penegor has resigned from Perrigo's board of directors, effective July 31, 2024, due to his expected appointment as CEO of another public company.

Perrigo Company plc has completed the divestment of its HRA Pharma Rare Diseases business to Esteve Healthcare, S.L. for a total consideration of up to 275 million.